logo
Plus   Neg
Share
Email

AstraZeneca : Selumetinib Granted Orphan Drug Designation In Japan For Neurofibromatosis Type 1

AstraZeneca (AZN.L,AZN) said that selumetinib has been granted orphan drug designation in Japan for the treatment of neurofibromatosis type 1 or NF1, a rare and debilitating genetic disease.

Selumetinib is co-developed and co-commercialised with Merck & Co.

The National Cancer Institute Cancer Therapy Evaluation Program-sponsored Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral monotherapy.

Overall response rate is defined as the percentage of patients with confirmed complete or partial response of at least 20% reduction in tumour volume.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Euromarket Designs, Inc., doing business as CB2, has recalled Junction tall chests and low dressers citing tip-over and entrapment hazards to children, according to the U.S. Consumer Product Safety Commission. The Chicago, Illinois - based company has called back about 11,000 units sold in the United States and about 355 units sold in Canada. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported a profit for the fourth-quarter that increased 23.3 percent from last year, led by display and memory chip businesses.Quarterly revenue grew 2.8 percent from the prior year. The company expects overall profit to weaken in the first quarter of 2021. Facebook Inc. (FB) Wednesday reported a fourth-quarter profit that increased from a year ago, driven largely by 33% growth in revenues. The social media giant's earnings and revenues for the quarter trumped Wall Street estimates, but the company warned of "significant uncertainty" in 2021. Menlo Park,...
Follow RTT